These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18163518)

  • 41. Lack of efficacy of rituximab in Felty's syndrome.
    Sordet C; Gottenberg JE; Hellmich B; Kieffer P; Mariette X; Sibilia J
    Ann Rheum Dis; 2005 Feb; 64(2):332-3. PubMed ID: 15647445
    [No Abstract]   [Full Text] [Related]  

  • 42. Discordant response to rituximab in a systemic sclerosis patient with associated myositis.
    Fabri M; Hunzelmann N; Krieg T; Rubbert A
    J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S127-8. PubMed ID: 18489049
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
    Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
    Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
    [No Abstract]   [Full Text] [Related]  

  • 44. Rituximab for treatment of scleritis associated with rheumatoid arthritis.
    Chauhan S; Kamal A; Thompson RN; Estrach C; Moots RJ
    Br J Ophthalmol; 2009 Jul; 93(7):984-5. PubMed ID: 19553514
    [No Abstract]   [Full Text] [Related]  

  • 45. [The use of cyclosporin A in the treatment of autoimmune disorders].
    Kurki P
    Duodecim; 1999; 115(6):659-66. PubMed ID: 11859500
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

  • 47. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab).
    Pinto LF; Candia L; Garcia P; Marín JI; Pachón I; Espinoza LR; Marquez J
    Respiration; 2009; 78(1):106-9. PubMed ID: 18799870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rituximab in lupus and beyond: the state of the art.
    Hughes G
    Lupus; 2009 Jun; 18(7):639-44. PubMed ID: 19433465
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales.
    Lowinger JS; Kaye KI
    Intern Med J; 2008 Feb; 38(2):146-8. PubMed ID: 18290836
    [No Abstract]   [Full Text] [Related]  

  • 50. New prospects for autoimmune disease therapy: B cells on deathwatch.
    St Clair EW; Tedder TF
    Arthritis Rheum; 2006 Jan; 54(1):1-9. PubMed ID: 16385491
    [No Abstract]   [Full Text] [Related]  

  • 51. Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome.
    Salama A; Schneider U; Dörner T
    Ann Rheum Dis; 2008 Jun; 67(6):894-5. PubMed ID: 18474659
    [No Abstract]   [Full Text] [Related]  

  • 52. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.
    Soriano ER; Galarza-Maldonado C; Cardiel MH; Pons-Estel BA; Massardo L; Caballero-Uribe CV; Achurra-Castillo AF; Barile-Fabris LA; Chávez-Corrales J; Díaz-Coto JF; Esteva-Spinetti MH; Guibert-Toledano M; Palazuelos FI; Keiserman MW; Lomonte AV; Mota LM; Pineda Villaseñor C; Alarcón GS;
    Rheumatology (Oxford); 2008 Jul; 47(7):1097-9. PubMed ID: 18463144
    [No Abstract]   [Full Text] [Related]  

  • 53. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
    Narváez J; Díaz-Torné C; Juanola X; Geli C; Llobet JM; Nolla JM; Díaz-López C
    Ann Rheum Dis; 2009 Apr; 68(4):607-8. PubMed ID: 19286909
    [No Abstract]   [Full Text] [Related]  

  • 54. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases.
    Looney RJ; Diamond B; Holers VM; Levesque MC; Moreland L; Nahm MH; St Clair EW;
    Clin Immunol; 2007 Jun; 123(3):235-43. PubMed ID: 17329169
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis.
    Burr ML; Malaviya AP; Gaston JH; Carmichael AJ; Ostör AJ
    Rheumatology (Oxford); 2008 May; 47(5):738-9. PubMed ID: 18375402
    [No Abstract]   [Full Text] [Related]  

  • 56. Trends in the development of therapeutic anti-cytokine antibodies.
    Reichert JM
    Drug Discov Today; 2004 Apr; 9(8):348. PubMed ID: 15081960
    [No Abstract]   [Full Text] [Related]  

  • 57. Effects of rituximab on resistant SLE disease including lung involvement.
    Reynolds JA; Toescu V; Yee CS; Prabu A; Situnayake D; Gordon C
    Lupus; 2009 Jan; 18(1):67-73. PubMed ID: 19074171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

  • 59. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.
    Stübgen JP
    J Neuroimmunol; 2008 Nov; 204(1-2):1-12. PubMed ID: 18783837
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.